ArticleBMC nephrology2026
Hemoglobinuria-associated acute kidney injury in hemolytic uremic syndrome without renal thrombotic microangiopathy.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemolytic uremic syndrome (HUS) is classically defined by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI) and is most often associated with renal thrombotic microangiopathy (TMA). However, the clinical triad may rarely occur in the absence of histologically demonstrable renal TMA. CASE PRESENTATION: A 64-year-old woman with hypertension treated with an ACE inhibitor presented with asthenia, nausea, dark urine, and oliguria. Laboratory evaluation revealed AKI (serum creatinine 4.5 mg/dL), thrombocytopenia (46 × 10⁹/L), and intravascular hemolysis (LDH > 1,800 U/L, schistocytes, haptoglobin < 10 mg/dL). Procalcitonin was markedly elevated, while complement levels and ADAMTS13 activity were within the normal range. Anti-factor H antibodies and complement genetic testing were negative; however, these findings do not exclude complement-mediated atypical HUS, which remains a diagnosis of exclusion. A positive direct Coombs test was documented at presentation. Paroxysmal nocturnal hemoglobinuria could not be definitively excluded, as flow cytometry was not performed. Mild, self-limited gastrointestinal symptoms preceded admission and may have acted as a triggering event. The patient was initially treated for suspected STEC-HUS with plasma exchange (subsequently discontinued), supportive therapy, and hemodialysis from day 3. Hematologic abnormalities resolved, whereas renal function worsened, with serum creatinine peaking at 10 mg/dL. Kidney biopsy performed on day 7 revealed acute tubular injury with hemoglobin pigment casts and no evidence of renal TMA. Dialysis was withdrawn, and renal recovery followed.
conclusionsThis case illustrates that in patients fulfilling the clinical triad classically associated with HUS, AKI does not invariably result from renal thrombotic microangiopathy. Hemoglobinuria-induced tubular injury may represent an alternative mechanism of renal injury. When hematologic recovery contrasts with persistent renal dysfunction, pigment nephropathy should be considered and kidney biopsy performed when feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.